HighTower Advisors LLC Buys 2,054 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

HighTower Advisors LLC increased its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 27.0% in the 4th quarter, Holdings Channel reports. The firm owned 9,648 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,054 shares during the period. HighTower Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $1,188,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the stock. Advisors Asset Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 3.9% in the third quarter. Advisors Asset Management Inc. now owns 9,624 shares of the specialty pharmaceutical company’s stock worth $1,072,000 after buying an additional 364 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Jazz Pharmaceuticals by 8.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 531,710 shares of the specialty pharmaceutical company’s stock valued at $59,238,000 after acquiring an additional 42,587 shares during the period. Cerity Partners LLC boosted its holdings in Jazz Pharmaceuticals by 128.4% during the third quarter. Cerity Partners LLC now owns 32,757 shares of the specialty pharmaceutical company’s stock valued at $3,650,000 after acquiring an additional 18,414 shares during the period. Loomis Sayles & Co. L P grew its position in shares of Jazz Pharmaceuticals by 2.7% in the third quarter. Loomis Sayles & Co. L P now owns 106,652 shares of the specialty pharmaceutical company’s stock valued at $11,882,000 after purchasing an additional 2,838 shares during the last quarter. Finally, Townsquare Capital LLC bought a new position in shares of Jazz Pharmaceuticals in the third quarter worth about $220,000. Institutional investors own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on JAZZ shares. Barclays restated an “overweight” rating and set a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the company from $145.00 to $179.00 in a research report on Friday, March 7th. Truist Financial raised their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. Royal Bank of Canada cut their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. Finally, Piper Sandler restated an “overweight” rating and set a $176.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $187.71.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $135.25 on Wednesday. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a market cap of $8.21 billion, a P/E ratio of 19.05, a PEG ratio of 1.04 and a beta of 0.44. The company’s 50-day simple moving average is $132.04 and its 200 day simple moving average is $122.23.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the sale, the executive vice president now owns 33,318 shares in the company, valued at $4,826,778.66. This trade represents a 10.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CMO Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the transaction, the chief marketing officer now directly owns 82,024 shares of the company’s stock, valued at $11,368,526.40. This represents a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,736 shares of company stock valued at $4,022,825. 4.20% of the stock is currently owned by corporate insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.